The identification and biochemical characterization of drug-like compounds that inhibit botulinum neurotoxin serotype A endopeptidase activity

Toxicon

Volumn 55, Issue 4, 2010, Pages 818-826

  Cai, Shuowei ^a   Lindo, Paul ^a   Park, Jong Beak ^a   Vasa, Kruti ^a   Singh, Bal Ram ^a  

^a UNIVERSITY OF MASSACHUSETTS DARTMOUTH   (United States)

Author keywords

Botulinum neurotoxin serotype A; Clostridial botulinum neurotoxins; Fluorescence resonance energy transfer; High throughput screening assay; Primary neuron based assay; Small molecular inhibitors

Indexed keywords

BOTULINUM TOXIN A; PROTEINASE; PROTEINASE INHIBITOR; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ANIMAL CELL; ARTICLE; BOTULISM; CELL CULTURE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; KINETICS; METABOLISM; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BOTULINUM TOXIN TYPE A; ENDOPEPTIDASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; KINETICS; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77953287092     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2009.11.017     Document Type: Article

References (34)

1. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett D.A., Scher M.S., Eitzen E., Fine A.D., Hauer J., Layton M., Lillibridge S., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Swerdlow D.L., Tonal K. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2000, 285:1059-1070.
2. Boldt G.E., Eubanks L.M., Janda K.D. Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model. Chem. Commun. (Camb) 2006, 7:3063-3065.
3. Breidenbach M.A., Brunger A.T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 2004, 432:925-929.
4. Burnett J.C., Schmidt J.J., Stafford R.G., Panchal R.G., Nguyen T.L., Hermone A.R., Vennerstrom J.L., McGrath C.F., Lane D.J., Sausville E.A., Zaharevitz D.W., Gussio R., Bavari S. Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem. Biophys. Res. Commun 2003, 310:84-93.
5. Burnett J.C., Schmidt J.J., McGrath C.F., Nguyen T.L., Hermone A.R., Panchal R.G., Vennerstrom J.L., Kodukula K., Zaharevitz D.W., Gussio R., Bavari S. Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding. Bioorg. Med. Chem. 2005, 13:333-341.
6. Burnett J.C., Opsenica D., Sriraghavan K., Panchal R.G., Ruthel G., Hermone A.R., Nguyen T.L., Kenny T.A., Lane D.J., McGrath C.F., Schmidt J.J., Vennerstrom J.L., Gussio R., Solaja B.A., Bavari S. A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease. J. Med. Chem. 2007, 50:2127-2136.
7. Burnett J.C., Ruthel G., Stegmann C.M., Panchal R.G., Nguyen T.L., Hermone A.R., Stafford R.G., Lane D.J., Kenny T.A., McGrath C.F., Wipf P., Stahl A.M., Schmidt J.J., Gussio R., Brunger A.T., Bavari S. Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J. Biol. Chem. 2007, 282:5004-5014.
8. Burnett J.C., Wang C., Nuss J.E., Nguyen T.L., Hermone A.R., Schmidt J.J., Gussio R., Wipf P., Bavari S. Pharmacophore-guided lead optimization: the rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease. Bioorg. Med. Chem. Lett. 2009, 19:5811-5813.
9. Cai S., Singh B.R. Strategies to design inhibitors of Clostridium botulinum neurotoxins. Infect. Disord.-Drug Targets 2007, 7:47-57.
10. Cai S., Sarkar H.K., Singh B.R. Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol. Biochemistry 1999, 38:6903-6910.
11. Cai S., Kukreja R., Shoesmith S., Chang T.W., Singh B.R. Botulinum neurotoxin light chain refolds at endosomal pH for its translocation. Protein J 2006, 25:455-462.
12. High Throughput Screening 1997, CRC Press. J.P. Devlin (Ed.).
13. Dickerson T.J., Janda K.D. The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication. ACS Chem. Biol. 2006, 1:359-369.
14. Greenfield R.A., Brown B.R., Hutchins J.B., Iandolo J.J., Jackson R., Slater L.N., Bronze M.S. Microbiological, biological, and chemical weapons of warfare and terrorism. Am. J. Med. Sci. 2002, 323:326-340.
15. Hermone A.R., Burnett J.C., Nuss J.E., Tressler L.E., Nguyen T.L., Solaja B.A., Vennerstrom J.L., Schmidt J.J., Wipf P., Bavari S., Gussio R. Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore. Chem. Med. Chem. 2008, 3:1905-1912.
16. Koriazova L.K., Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat. Struct. Biol. 2003, 10:13-18.
17. Li L., Singh B.R. Structure-function relationship of clostridial neurotoxins. J. Toxicol.-Toxin Rev. 1999, 18:95-112.
18. Li L., Singh B.R. High-level expression, purification, and characterization of recombinant type A botulinum neurotoxin light chain. Protein Expr. Purif. 1999, 17:339-344.
19. Montecucco C. How do tetanus and botulinum toxins bind to neuronal membranes?. Trends Biochem. Sci. 1986, 11:314-317.
20. Montecucco C., Schiavo G. Tetanus and botulism neurotoxins: a new group of zinc proteases. Trends Biochem. Sci. 1993, 18:324-327.
21. Montecucco C., Schiavo G. Structure and function of tetanus and botulinum neurotoxins. Q. Rev. Biophys 1995, 28:423-472.
22. Montecucco C., Rossetto O., Schiavo G. Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol. 2004, 12:442-446.
23. Poulain B., Popoff M.R., Molgo J. How do the botulinum neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. Botulinum J 2008, 1:14-87.
24. Rosenbloom M., Leikin J.B., Vogel S.N., Chaudry Z.A. Biological and chemical agents: a brief synopsis. Am. J. Therapeut 2002, 9:5-14.
25. Rossetto O., Seveso M., Caccin P., Schiavo G., Montecucco C. Tetanus and botulinum neurotoxins: turning bad guys into good by research. Toxicon 2001, 39:27-41.
26. Schmidt J.J., Stafford R.G., Millard C.B. High-throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F. Anal. Biochem 2001, 296:130-137.
27. Sharma S.K., Singh B.R. Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins. Biochemistry 2004, 43:4791-4798.
28. Simpson L.L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol 2004, 44:167-193.
29. Singh B.R. Intimate details of the most poisonous poison. Nat. Struct. Biol. 2000, 7:617-619.
30. Singh B.R. Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting. Neurotox. Res. 2006, 9:73-92.
31. Skaper S.D., Adler R., Varon S. A procedure for purifying neuron-like cells in cultures from central nervous tissue with a defined medium. Dev. Neurosci 1979, 2:233-237.
32. Wein L.M., Liu Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc. Natl. Acad. Sci. USA 2005, 102:9984-9989.
33. Zhang J.H., Chung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 1999, 4:67-73.
34. Zuniga J.E., Schmidt J.J., Fenn T., Burnett J.C., Araç D., Gussio R., Stafford R.G., Badie S.S., Bavari S., Brunger A.T. A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate. Structure 2008, 16:1588-1597.